Quantitative analysis for Apnimed Inc. Common Stock (APMD) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Buy (100.0) (grade A). Gem alpha score: 61.0. 32 signals analyzed (26 differentiated alt-data).
APMD stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-07-29 | $16.00 | $16.00 | $16.00 |
| 2026-08-03 | $27.91 | $22.35 | $25.00 |
| 2026-08-06 | $28.45 | $25.13 | $27.88 |
| 2026-08-11 | $28.25 | $24.61 | $24.87 |
| 2026-08-14 | $33.10 | $28.06 | $31.75 |
| 2026-08-19 | $33.12 | $31.07 | $32.03 |
| 2026-08-24 | $27.83 | $25.33 | $25.63 |
| 2026-08-27 | $31.09 | $28.33 | $28.72 |
| 2026-09-01 | $27.88 | $25.11 | $26.85 |
| 2026-09-04 | $28.36 | $26.44 | $27.45 |
| 2026-09-10 | $28.74 | $26.59 | $26.80 |
| 2026-09-15 | $26.83 | $25.05 | $25.56 |
How Apnimed Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
View all Health Care stocks by valuation and signals →
Apnimed Inc. Common Stock (APMD) scores Strong Buy (100.0), and the composite conceals a 99-point disagreement between its dimensions. It is strongest on technicals at 100 and AI Alpha (gem) at 99, and weakest on analyst consensus at 8 and competitive moat at 1. A stock can carry technicals that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 100 |
| AI Alpha (gem) | 99 |
| social sentiment | 95 |
| analyst consensus | 8 |
| competitive moat | 1 |
StoQuant analyzes 32 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Apnimed Inc. Common Stock (APMD): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/APMD"><img src="https://stoquant.com/badge/APMD.svg" alt="Apnimed Inc. Common Stock (APMD) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.